MONTREAL, QUEBEC--(Marketwired - April 29, 2014) - Knight Therapeutics Inc. ("Knight") (TSX:GUD) announced that later today its common shares will commence trading on Toronto Stock Exchange. At this same time, its common shares will be de-listed from TSX Venture Exchange.
Jonathan Ross Goodman, Chief Executive Officer of Knight and Founder of both Paladin Labs Inc. ("Paladin") and Knight, stated "It took Paladin 5 years to graduate to the Toronto Stock Exchange. It has taken Knight less than 2 months to do the same. That being said, it took Paladin 19 years to become an overnight success and once again we expect that patience will be handsomely rewarded."
About Knight Therapeutics Inc.:
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight Therapeutics' shares began trading on the TSX-V on March 3, 2014 under the symbol GUD. For more information about Knight Therapeutics, please visit the Company's web site at www.gud-knight.com or at www.sedar.com.
This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the Company's final application for listing on the TSX Venture Exchange and can be found on SEDAR at www.sedar.com, which investors should consult for additional information. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.
Neither TSX, TSX Venture Exchange nor their Regulation Services Providers (as that term is defined in policies of the TSX and TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information:
514-484-4483